Genetic medicines to cure patients with life-threatening diseases
We develop transformative mRNA therapies by leveraging our ground-breaking proprietary delivery technology, machine learning and superior nucleic acid engineering.
Delivery development
Our programmable, scalable, and non-immunogenic nanocarriers can target tissues and cell types beyond the liver and highly outperform leading delivery technologies.
Machine learning
Our trained ML models predict carrier quality and performance to guide us in choosing the best candidates from a library of millions of distinct carriers. See Publication →
Genetic payload engineering
Drug development
About Us
We are a team of passionate scientists and entrepreneurs, collaborating with expert scientific and business advisors.
Benita Nagel
Co-founder & CEO
Albert Kwok, PhD
Co-founder & CSO
Mark Wolters, PhD
Business Development
Lawrence Billing, PhD
Asset Development
Tristan Henser, PhD
Machine Learning
Adam Leach, PhD
mRNA Engineering
Liam Martin, PhD
Delivery Chemistry
Parisa Samangouei, PhD
Delivery Biology
Aaqib Ladak
Delivery Biology
Marina Apostolidou
Delivery Chemistry
Media
News
August 20, 2024
Deals Report: Delivery play Nuntius out of stealth with Taiho cancer deal
Read More
News
August 16, 2024
Nuntius Therapeutics Emerges from Stealth, Announces Taiho Pharmaceutical Partnership
Read More
Press Release
August 15, 2024
Nuntius Therapeutics announces collaboration with Taiho Pharmaceutical to develop next-generation mRNA therapies using Nuntius’ proprietary cell-specific delivery technology
Read More
Publication
June 5, 2024
In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery
Read More
Join our team
We are looking for exceptional individuals who want to push the frontiers of science and are driven by patient outcome. Check out our open positions or email us at careers@nuntiustx.com.
